ReNeuron gains UK regulatory approval to start ground-breaking clinical trial with stem cell therapy for stroke . 19/01/09

Guildford, UK, 19 January 2009: ReNeuron Group plc (LSE: RENE.L) today announces that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a first-in-man clinical trial for the treatment of patients who have been left disabled by an ischaemic stroke, the most common form of the condition. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world.

More…

ReNeuron to present on diabetes therapy at UK biotechnology conference . 12/12/07

Guildford, UK, 11 December 2007: ReNeuron Group plc (LSE: RENE.L) today announces that it will be participating in the London Biotechnology Network’s 7th Annual Genesis Conference, on 13-14 December 2007. Dr John Sinden, Chief Scientific Officer of ReNeuron, will give a development update on the Company’s ReN002 therapy for Type 1 diabetes, as part of the UK Biotechnology Company Showcase event on 14 December, at the BERR Conference Centre, London.

More…

Interim Results for the six months ended 30 September 2007. 03/12/07

Summary of interim results:

  • Successful completion of further pre-clinical studies in support of IND application to commence initial clinical trial in the US with ReN001 stem cell therapy for stroke
  • Amendments to IND application completed and filed with FDA
  • Insulin-producing islets generated in ReN002 diabetes programme
  • Acquisition of business assets of AmCyte for US$4.0 million, together with further £1.5 million fundraising before expenses, both achieved via share placing
  • Research collaboration initiated with King’s College London regarding enhancements to stem cell expansion technology
  • Other therapeutic and non-therapeutic programmes progressing to plan
  • Net loss of £3.1 million (2006: £3.3 million); net cash outflow from operating activities £2.9 million (2006: £3.0 million); cash and cash equivalents at 30 September 2007 of £5.7 million (2006: £2.8 million)

More…

ReNeuron to present at BMO Capital Markets US healthcare conference. 28/11/07

Guildford, UK, 28 November 2007: ReNeuron Group plc (LSE: RENE.L) today announces that it will be participating in the BMO Capital Markets Focus on Healthcare Conference, taking place at the Millennium Broadway Hotel, New York City on 4-5 December 2007. Michael Hunt, Chief Executive Officer of ReNeuron, will give an update on the Company’s activities and recent progress, scheduled for 3:00pm EST on 5 December.

More…

ReNeuron welcomes ground-breaking research on gene-based reprogramming of human stem cells. 21/11/07

Guildford, UK, 21 November 2007: ReNeuron Group plc (LSE:RENE.L) today welcomes the publication of ground-breaking research into the reprogramming of adult human stem cells undertaken by teams lead by Shinya Yamanaka and James Thomson of, respectively, Kyoto University and the University of Wisconsin-Madison.

More…

Notification of 2007 Interim Results. 28/11/07

Guildford, UK, 28 November 2007: ReNeuron Group plc (LSE: RENE.L) today announces that it will report its interim results for the six months ended 30 September 2007 on Monday 3 December 2007.

More…

ReNeuron to present positive pre-clinical data concerning its ReN005 stem cell line for Huntington's disease. 18/10/07

Guildford, UK, 18 Oct 2007: ReNeuron Group plc (LSE: RENE.L) today announces that it will be participating in the 3rd World Congress on Regenerative Medicine, taking place at The Congress Center, Leipzig, Germany on 18-20 October. The Company will present in the Neurodegeneration and Repair stream on the morning of 20 October.

More…

Results of 2007 Annual General Meeting. 06/09/07

Guildford, UK, 6 September 2007: ReNeuron Group plc (LSE: RENE) announces that all resolutions put to its shareholders at today’s 2007 Annual General Meeting were passed.

More…

ReNeuron announces compliance with AIM Rule 26. 20/08/07

ReNeuron Group plc (LSE: RENE.L) is pleased to announce that the information required by Rule 26 of the AIM Rules for Companies (Company Information Disclosure) is available on ReNeuron’s website at www.reneuron.com.

More…

Notification of increase in issued share capital. 07/08/07

Guildford, UK: ReNeuron Group plc (LSE: RENE.L) announces that on 1 August 2007 it allotted and issued 16,476,190 new ordinary shares of 1 pence each in connection with the acquisition of the business and assets of AmCyte and the placing of new ordinary shares with investors to provide working capital for the acquired business for at least the next year. Further details of such acquisition and placing are set out in ReNeuron’s press release of 27 July 2007.

More…